| Product NDC: | 10019-115 | 
| Proprietary Name: | Brevibloc | 
| Non Proprietary Name: | Esmolol Hydrochloride | 
| Active Ingredient(s): | 10 mg/mL & nbsp; Esmolol Hydrochloride | 
| Administration Route(s): | INTRAVENOUS | 
| Dosage Form(s): | INJECTION | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 10019-115 | 
| Labeler Name: | Baxter Healthcare Corporation | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | NDA019386 | 
| Marketing Category: | NDA | 
| Start Marketing Date: | 19861231 | 
| Package NDC: | 10019-115-01 | 
| Package Description: | 25 VIAL in 1 CARTON (10019-115-01) > 10 mL in 1 VIAL (10019-115-39) | 
| NDC Code | 10019-115-01 | 
| Proprietary Name | Brevibloc | 
| Package Description | 25 VIAL in 1 CARTON (10019-115-01) > 10 mL in 1 VIAL (10019-115-39) | 
| Product NDC | 10019-115 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | Esmolol Hydrochloride | 
| Dosage Form Name | INJECTION | 
| Route Name | INTRAVENOUS | 
| Start Marketing Date | 19861231 | 
| Marketing Category Name | NDA | 
| Labeler Name | Baxter Healthcare Corporation | 
| Substance Name | ESMOLOL HYDROCHLORIDE | 
| Strength Number | 10 | 
| Strength Unit | mg/mL | 
| Pharmaceutical Classes | Adrenergic beta-Antagonists [MoA],beta-Adrenergic Blocker [EPC] |